Table 3.
Selected adverse events
| Patients, n (%) | G-FC (n = 21) | G-B (n = 20) | ||
|---|---|---|---|---|
| All grades | Grade 3-4 | All grades | Grade 3-4 | |
| All AEs | 21 (100) | 18 (86) | 20 (100) | 17 (85) |
| Hematologic AE | ||||
| Neutropenia | 6 (29) | 6 (29) | 10* (50) | 10 (50) |
| Febrile neutropenia | 4 (19) | 4 (19) | 2* (10) | 2 (10) |
| Thrombocytopenia | 4 (19) | 4 (19) | 4 (20) | 2 (10) |
| Anemia | 5 (24) | 3 (14) | 3 (15) | 1 (5) |
| Infections | 11 (52) | 4 (19) | 9 (45) | 1 (5) |
| Tumor lysis syndrome | 0 | 0 | 1 (5) | 1 (5) |
| Laboratory investigations | ||||
| Elevation in hepatic transaminases | 4 (19) | 4 (19) | 2 (10) | 2 (10) |
*
The total number of patients treated with G-B who experienced grade 3-4 neutropenia was 11 (55%), as 1 patient was reported to have both febrile neutropenia and grade 3-4 neutropenia.